-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Novavax COVID-19 Omicron vaccine
Therapeutic area | Infectious disease | Status | Technology |
---|---|---|---|
Respiratory diseases | COVID-19 | Preclinical | Matrix-M™ adjuvant |
Therapeutic area
Respiratory diseases
Infectious disease
COVID-19
Status
Preclinical
Technology
Matrix-M™ adjuvant
About the candidate
As the SARS-CoV-2 virus continues to evolve, Novavax is evaluating a variant strain vaccine based on the Omicron (B.1.1.529) Variant of Concern (VOC).
In December 2021, Novavax began developing an Omicron-specific variant vaccine and within weeks we initiated GMP manufacturing. Novavax expects to begin clinical studies of this candidate in Q2 2022.